NZ333315A - Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions - Google Patents
Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditionsInfo
- Publication number
- NZ333315A NZ333315A NZ333315A NZ33331597A NZ333315A NZ 333315 A NZ333315 A NZ 333315A NZ 333315 A NZ333315 A NZ 333315A NZ 33331597 A NZ33331597 A NZ 33331597A NZ 333315 A NZ333315 A NZ 333315A
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- optionally
- alkyl
- hydrogen atom
- chelating agents
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Semiconductor Lasers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
| PCT/GB1997/001722 WO1997049409A1 (en) | 1996-06-24 | 1997-06-24 | Chelating agents and their metal chelates for treating free radicals induced conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333315A true NZ333315A (en) | 2000-07-28 |
Family
ID=10795775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333315A NZ333315A (en) | 1996-06-24 | 1997-06-24 | Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions |
| NZ333357A NZ333357A (en) | 1996-06-24 | 1997-06-24 | Reduction of cardiotoxicity of an antitumor agent using manganese compound |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333357A NZ333357A (en) | 1996-06-24 | 1997-06-24 | Reduction of cardiotoxicity of an antitumor agent using manganese compound |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6258828B1 (OSRAM) |
| EP (2) | EP0936915B1 (OSRAM) |
| JP (2) | JP4162263B2 (OSRAM) |
| CN (2) | CN1228694A (OSRAM) |
| AT (2) | ATE225178T1 (OSRAM) |
| AU (2) | AU720570B2 (OSRAM) |
| BR (1) | BR9709942A (OSRAM) |
| CA (2) | CA2258299A1 (OSRAM) |
| DE (2) | DE69716104T2 (OSRAM) |
| GB (1) | GB9613182D0 (OSRAM) |
| IL (1) | IL127733A0 (OSRAM) |
| NO (2) | NO985917L (OSRAM) |
| NZ (2) | NZ333315A (OSRAM) |
| WO (2) | WO1997049409A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| JP2001527072A (ja) | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| EP2327713A1 (en) | 1999-10-01 | 2011-06-01 | DMI Biosciences, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| FR2823977B1 (fr) * | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| ES2388064T3 (es) | 2004-04-22 | 2012-10-08 | Celator Pharmaceuticals, Inc. | Formulaciones liposomales de agentes de antraciclina y análogos de citidina |
| PL3311805T3 (pl) | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| RU2491282C2 (ru) | 2007-12-14 | 2013-08-27 | Пледфарма Аб | Соединения, предназначенные для лечения рака |
| CA2767339C (en) * | 2009-07-06 | 2016-05-24 | Pledpharma Ab | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
| EP2707030B1 (en) | 2011-05-09 | 2020-02-19 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US20150313921A1 (en) | 2012-11-02 | 2015-11-05 | Pledpharma Ab | Cancer Treatment Methods |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| KR102462041B1 (ko) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| JP7025412B2 (ja) | 2016-09-06 | 2022-02-24 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
| US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
| US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en not_active Ceased
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 EP EP97928369A patent/EP0936915B1/en not_active Expired - Lifetime
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en not_active Ceased
- 1997-06-24 EP EP97928368A patent/EP0910360B1/en not_active Expired - Lifetime
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
-
1998
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ333357A (en) | 2000-08-25 |
| CN1228694A (zh) | 1999-09-15 |
| WO1997049390A1 (en) | 1997-12-31 |
| JP2000513351A (ja) | 2000-10-10 |
| AU3268897A (en) | 1998-01-14 |
| GB9613182D0 (en) | 1996-08-28 |
| DE69716104T2 (de) | 2003-05-28 |
| DE69717447D1 (de) | 2003-01-09 |
| NO985916L (no) | 1999-01-25 |
| EP0936915B1 (en) | 2002-10-02 |
| NO985917D0 (no) | 1998-12-17 |
| AU720621B2 (en) | 2000-06-08 |
| NO985916D0 (no) | 1998-12-17 |
| US6147094A (en) | 2000-11-14 |
| DE69717447T2 (de) | 2003-09-11 |
| ATE228361T1 (de) | 2002-12-15 |
| WO1997049409A1 (en) | 1997-12-31 |
| US6258828B1 (en) | 2001-07-10 |
| ATE225178T1 (de) | 2002-10-15 |
| JP2000514044A (ja) | 2000-10-24 |
| IL127733A0 (en) | 1999-10-28 |
| DE69716104D1 (de) | 2002-11-07 |
| EP0936915A1 (en) | 1999-08-25 |
| BR9709942A (pt) | 1999-08-10 |
| AU3268997A (en) | 1998-01-14 |
| CA2258299A1 (en) | 1997-12-31 |
| JP4359651B2 (ja) | 2009-11-04 |
| NO985917L (no) | 1999-01-25 |
| EP0910360B1 (en) | 2002-11-27 |
| JP4162263B2 (ja) | 2008-10-08 |
| AU720570B2 (en) | 2000-06-08 |
| EP0910360A1 (en) | 1999-04-28 |
| CN1228703A (zh) | 1999-09-15 |
| CA2259150A1 (en) | 1997-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ333315A (en) | Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions | |
| ATE270553T1 (de) | Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren | |
| ATE411026T1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
| ATE207759T1 (de) | Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels | |
| DK295888D0 (da) | Monoaminacridiner, farmaceutiske midler indeholdende disse samt anvendelse deraf til behandling af cholinerge neuronale mangeltilstande. | |
| ATE210129T1 (de) | Neue pyridoncarbonsäure-derivate oder ihre salze und antibakterielle mittel, die diese als aktiven wirkstoff enthalten | |
| FI101705B1 (fi) | Menetelmä aralifaattisesti N-substituoitujen aminoalkaanifosfiinihappojen valmistamiseksi | |
| DE69430816D1 (de) | Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie | |
| ZA924267B (en) | Fluorophenyl amides and their use in therapy | |
| EP0699439A3 (en) | Treatment of diseases caused by sebum with inhibitors of acyl CoA cholesterol acyltransferase | |
| DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen | |
| DE69634200D1 (de) | Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung | |
| ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
| ATE169217T1 (de) | Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten | |
| PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro | |
| ATE290379T1 (de) | Verwendung von chelatbildnern zur behandlung atherosklerotischer beschwerden | |
| ATE369856T1 (de) | Verfahren zur behandlung von glaukom | |
| NZ511559A (en) | Use of staurosporine derivatives for treating ocular neovascular diseases | |
| NO20003481L (no) | FremgangsmÕte for behandling av COPD | |
| ATE236881T1 (de) | Durch strahlung aktivierte cytotoxin therapie | |
| DE69633673D1 (de) | Verwendung von Halofuginon zur Herstellung eines Medikaments zur Vorbeugung von Neovaskularisation und zur Behandlung bösartiger Tumore | |
| DE69627298D1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
| ES466795A1 (es) | Un procedimiento para la produccion de imidazo(1,5-b)pirida-zinas | |
| ATE200865T1 (de) | Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien | |
| BR0012495A (pt) | Métodos para o tratamento de uma indicação resultante de uma resposta mediada por ige em um mamìfero, para a regulação descendente de um receptor para ige e de ligante cd40, e, para a inibição da secreção de ige por plasmócitos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |